Efficacy of Taletrectinib (AB-106/DS-6051b) in ROS1+ NSCLC: An Updated Pooled Analysis of U.S. and Japan Phase 1 Studies

by Sai-Hong Ignatius Ou, MD, PhD, Yutaka Fujiwara, MD, PhD, Alice T. Shaw, MD, PhD, Noboru Yamamoto, MD, PhD, Kazuhiko Nakagawa, MD, PhD, Frank Fan, MD, Yuki Hao, MSc, Yanfei Gao, MSc, Pasi A. Jänne, MD, Takashi Seto, MD
Published 2021-01-01

Efficacy and Safety of S-1 Compared With Docetaxel in Elderly Patients With Advanced NSCLC Previously Treated With Platinum-Based Chemotherapy: A Subgroup Analysis of the EAST-LC T...

by James Chih-Hsin Yang, MD, PhD, Tony S.K. Mok, MD, Shun Lu, MD, Kazuhiko Nakagawa, MD, PhD, Nobuyuki Yamamoto, MD, Yuan-Kai Shi, MD, Li Zhang, MD, Ross A. Soo, M.B.B.S., PhD, Satoshi Morita, PhD, Tomohide Tamura, MD
Published 2021-03-01

Clinical Efficacy and Safety of Nivolumab in Japanese Patients With Malignant Pleural Mesothelioma: 3-Year Results of the MERIT Study

by Nobukazu Fujimoto, MD, PhD, Morihito Okada, MD, PhD, Takashi Kijima, MD, PhD, Keisuke Aoe, MD, PhD, Terufumi Kato, MD, Kazuhiko Nakagawa, MD, PhD, Yuichiro Takeda, MD, PhD, Toyoaki Hida, MD, PhD, Kuninobu Kanai, MD, PhD, Jun Hirano, MPharm, Yuichiro Ohe, MD, PhD
Published 2021-03-01

Pembrolizumab Plus Amrubicin in Patients With Relapsed SCLC: Multi-Institutional, Single-Arm Phase 2 Study

by Hiroaki Akamatsu, MD, PhD, Shunsuke Teraoka, MD, Hidetoshi Hayashi, MD, PhD, Daichi Fujimoto, MD, Atsushi Hayata, MD, PhD, Koji Haratani, MD, PhD, Yuichi Ozawa, MD, PhD, Takeshi Yoshida, MD, PhD, Tsutomu Iwasa, MD, PhD, Toshio Shimokawa, MD, Keisuke Tomii, MD, PhD, Kazuhiko Nakagawa, MD, PhD, Nobuyuki Yamamoto, MD, PhD
Published 2021-07-01

Phase 2 Study of YS110, a Recombinant Humanized Anti-CD26 Monoclonal Antibody, in Japanese Patients With Advanced Malignant Pleural Mesothelioma

by Kazuhiko Nakagawa, MD, PhD, Takashi Kijima, MD, PhD, Morihito Okada, MD, PhD, Masahiro Morise, MD, PhD, Motoyasu Kato, MD, PhD, Katsuya Hirano, MD, Nobukazu Fujimoto, MD, PhD, Mitsuhiro Takenoyama, MD, PhD, Hiroshi Yokouchi, MD, PhD, Yuichiro Ohe, MD, PhD, Toyoaki Hida, MD, PhD, Keisuke Aoe, MD, PhD, Takumi Kishimoto, MD, PhD, Masato Hirokawa, MSc, Hironori Matsuki, MEng, Yutaro Kaneko, BSc, Taketo Yamada, MD, PhD, Chikao Morimoto, MD, PhD, Masayuki Takeda, MD, PhD
Published 2021-06-01

Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated Metastatic EGFR-Mutated NSCLC: RELAY Japanese Subset

by Kazuto Nishio, MD, PhD, Takashi Seto, MD, Makoto Nishio, MD, PhD, Martin Reck, MD, PhD, Edward B. Garon, MD, MS, Kazuko Sakai, PhD, Koichi Goto, MD, PhD, Terufumi Kato, MD, Yoichi Nakanishi, MD, PhD, Toshiaki Takahashi, MD, PhD, Nobuyuki Yamamoto, MD, PhD, Katsuyuki Kiura, MD, PhD, Yuichiro Ohe, MD, PhD, Tomohide Tamura, MD, Carla Visseren-Grul, MD, Bente Frimodt-Moller, MSc, Rebecca R. Hozak, PhD, Sameera R. Wijayawardana, PhD, Annamaria Zimmermann, MS, Gosuke Homma, PhD, Sotaro Enatsu, MD, PhD, Kazuhiko Nakagawa, MD, PhD
Published 2021-06-01